Neuromyelitis optica spectrum disorder
Adjust the patient characteristics. Results update as you go. Full criteria table
Draft. Coverage criteria for NMOSD preventive therapies in Alberta, adults only in this version. The special authorization criteria for inebilizumab, ravulizumab and satralizumab are verified verbatim against Alberta Drug Benefit List Section 3 effective April 1, 2026 (form ABC 60116). Entries for conventional therapies and for private and federal payers remain draft.